New Technology– category –
-
In Vivo CAR T Generation: CRISPR Two-Vector System for Cancer
The Medicine Maker USA Overview Researchers from the University of California and the Gladstone-UCSF Institute of Genomic Immunology have developed a two-vector delivery system that generates tumor-targeting CAR T cells directly inside t... -
Daraxonrasib: First RAS inhibitor FDA approval specs for 2026
American Association for Cancer Research (AACR) USA Overview The FDA granted several oncology approvals in Q3 2026, including the groundbreaking approval of Daraxonrasib (Rasonque), the first RAS inhibitor for pancreatic cancer. Addition... -
3D Bioprinting: Multi-layered tumor organoid specs for 2026
BIOENGINEER.ORG USA Overview Advances in 3D bioprinting have enabled the creation of multi-layered tumor organoid models that accurately replicate vascular structures, stromal compartments, and tumor-stroma interactions. This novel model... -
3D Bioprinting: Tsinghua University vascular organoid specs
Scienmag China Overview Researchers at Tsinghua University reported in BMC Medicine that 3D bioprinted human vascular organoid sheets effectively form functional vascular networks and restore blood flow in ischemic limbs. These sheets in... -
FAYUVI: Ultragenyx AAV9 gene therapy FDA approval and specs
DeciBio USA Overview Ultragenyx's AAV9 gene therapy FAYUVI (rebisufligene etisparvovec-hopf) has gained full FDA approval for pediatric patients with Sanfilippo Syndrome Type A (MPS IIIA), marking the first gene therapy approved for this... -
VIPR system: Jennifer Doudna’s discovery of CRISPR ancestor
The Times of India India Overview A research team led by Nobel laureate Jennifer Doudna at the Innovative Genomics Institute (IGI) has discovered the 'VIPR system' in viruses, which utilizes a previously unknown 'gapped' DNA coding strat... -
Sanfilippo Syndrome Type A: FDA approves first gene therapy
Vertex AI Search (Neurology News Outlet) USA Overview The U.S. FDA has approved a gene therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA), a devastating childhood dementia characterized by progressive neurodegeneration. ... -
APOE4 explained: Reversible weakness in Alzheimer’s risk gene
ScienceDaily USA Overview ScienceDaily reports the discovery of a potential reversible weakness in APOE4, a major genetic risk factor for Alzheimer's Disease (AD). This research identifies specific mechanisms by which APOE4 causes neuron... -
Beam Therapeutics’ In Vivo Base Editor BEAM-302 Increases Functional AAT by 93% in AATD Patients, Transforming Long-Term Disease Risk to Carrier Status
Seeking Alpha USA Overview Beam Therapeutics' in vivo base editing therapeutic, BEAM-302, presented groundbreaking long-term follow-up data in Alpha-1 Antitrypsin Deficiency (AATD) patients. The therapy demonstrated sustained in vivo gen... -
Gut Metabolites Impact CAR-T Therapy Efficacy: Butyrate and Indoles Linked to Enhanced Long-Term Remission and Survival in 129 Patient Clinical Data
Ludwig-Maximilians-Universität München Germany Overview Researchers at Ludwig-Maximilians-Universität München published in 'Cell' that human gut metabolites significantly influence CAR-T cell therapy clinical outcomes. Analyzing 129 pati...
